Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 199 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Mallinckrodt Clear all
Withdrawn Phase 4 Interventional

Early iNO for Oxidative Stress, Vascular Tone and Inflammation in Babies With Hypoxic Respiratory Failure

NCT01891500
View directory record Official record
Conditions
Persistent Fetal Circulation Syndrome, Hypertension, Pulmonary, of Newborn, Persistent, Persistent Pulmonary Hypertension of Newborn
Interventions
Inhaled nitric oxide, Nitrogen Gas, Crossover iNO
Drug
Lead sponsor
University of Florida
Other
Eligibility
30 Minutes to 48 Hours
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 4 Interventional Results available

Treatment of CNS Sarcoidosis With H.P. Acthar Gel

NCT02298491
View directory record Official record
Conditions
CNS Sarcoidosis
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets

NCT00853736
View directory record Official record
Conditions
Healthy
Interventions
Roxicodone™ tablet 30 mg, Oxycodone hydrochloride tablet 30 mg
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 4 Interventional

Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A

NCT00221039
View directory record Official record
Conditions
Cutaneous T Cell Lymphoma, Mycosis Fungoides
Interventions
Methoxsalen+ECP
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
7
States / cities
Chicago, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 2, 2026, 1:04 PM EDT
Terminated Phase 3 Interventional

A Randomized, Open Label, Prospective Study to Explore the Clinical Characteristics of Oral MNK155 and Norco 7.5mg/325 When Used for the Treatment of Moderate to Severe Post Operative Pain

NCT02381132
View directory record Official record
Conditions
Post Operative Pain
Interventions
Norco 7.5mg/325, MNK155
Drug
Lead sponsor
Neil Singla
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2016 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence of a Test Troche Formulation of Fentanyl Citrate (400 mcg) Compared to Actiq® 400 mcg, Cephalon, Inc.

NCT01173627
View directory record Official record
Conditions
Pain
Interventions
Test fentanyl citrate 400 mcg troche, Actiq 400 mcg
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

Acthar in Treatment of Refractory Dermatomyositis and Polymyositis

NCT01906372
View directory record Official record
Conditions
Dermatomyositis, Polymyositis
Interventions
Adrenocorticotropic Hormone Gel
Drug
Lead sponsor
Rohit Aggarwal, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Great Neck, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Bioavailability and Safety of PENNSAID® Gel

NCT01202799
View directory record Official record
Conditions
Pain
Interventions
2% w/w diclofenac sodium topical gel, 1.5% w/w diclofenac sodium topical solution, 75 mg diclofenac sodium delayed release tablet
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 2, 2026, 1:04 PM EDT
Terminated Phase 4 Interventional Results available

Pharmacokinetics (PK) and Safety Study of XARTEMIS® XR in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain

NCT02508935
View directory record Official record
Conditions
Acute Pain
Interventions
XARTEMIS XR
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
12 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Durham, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Early Phase 1 Interventional

Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)

NCT03727776
View directory record Official record
Conditions
Proliferative Vitreoretinopathy
Interventions
Adrenocorticotropic Hormone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

NCT03097861
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
67
States / cities
Birmingham, Alabama • Foley, Alabama • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 4 Interventional Results available

Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis

NCT02919761
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Acthar Gel, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
30
States / cities
San Leandro, California • Upland, California • Boynton Beach, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 2, 2026, 1:04 PM EDT
Withdrawn Phase 4 Interventional

ACTHAR Therapy for Central Nervous System Sarcoidosis

NCT02920710
View directory record Official record
Conditions
Sarcoidosis
Interventions
Repository Corticotropin Injection
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet Activation

NCT03455218
View directory record Official record
Conditions
Inflammation, Platelet Dysfunction
Interventions
Nitric Oxide, Placebo, INOmax
Drug · Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 1 Year
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone

NCT00595946
View directory record Official record
Conditions
Opioid-Induced Bowel Dysfunction
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
94
States / cities
Birmingham, Alabama • Hueytown, Alabama • Mobile, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant

NCT00639717
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), etanercept, methoxsalen
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

IV vs Oral Acetaminophen in Spine Fusion Perioperative Care

NCT03020875
View directory record Official record
Conditions
Multimodal Analgesic Approach
Interventions
Ofirmev, Per Os Acetaminophen
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 85 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Analgesic Efficacy of Intravenous Acetaminophen After Video-assisted Thoracic Surgery

NCT01783236
View directory record Official record
Conditions
Lung Tumor
Interventions
IV Acetaminophen, Saline Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients

NCT00598559
View directory record Official record
Conditions
Acute Pain, Fever
Interventions
IV Acetaminophen
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 85 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
14
States / cities
Arcadia, California • Glendale, California • Laguna Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 4 Interventional Results available

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

NCT01386554
View directory record Official record
Conditions
Proteinuria, Idiopathic Membranous Nephropathy
Interventions
Repository Corticotropin Injection, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
Sacramento, California • Stanford, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 2, 2026, 1:04 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia

NCT00850993
View directory record Official record
Conditions
Hyperbilirubinemia, Neonatal
Interventions
Stannsoporfin, Placebo, PhotoTherapy (as needed)
Drug · Other
Lead sponsor
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Industry
Eligibility
1 Minute to 48 Hours
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Colton, California • San Diego, California • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 4 Interventional Results available

Acthar Gel in Participants With Pulmonary Sarcoidosis

NCT03320070
View directory record Official record
Conditions
Sarcoidosis, Pulmonary
Interventions
Acthar Gel, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 90 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 2, 2026, 1:04 PM EDT
Terminated Phase 3 Interventional Results available

Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease

NCT02524847
View directory record Official record
Conditions
Steroid Refractory Acute Graft Versus Host Disease
Interventions
Methoxsalen, Extracorporeal Photopheresis (ECP)
Drug · Procedure
Lead sponsor
Therakos, Inc., a Mallinckrodt Company
Industry
Eligibility
1 Year to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

The Effects of Nitric Oxide for Inhalation During Left Ventricular Assists Device (LVAD) Implantation

NCT00060840
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Nitric Oxide, Nitrogen
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
8
States / cities
Newark, New Jersey • Durham, North Carolina • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Oct 2, 2026, 1:04 PM EDT